Form 8-K · Current report
Bristol Myers Squibb 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000014272
- Accession no.
- 0000014272-26-000022
Summary
Bristol Myers Squibb reported third-quarter 2026 revenues of $13.1 billion, up 7%, and raised its full-year revenue guidance to $49.75–$50.25 billion, with GAAP EPS of $1.05 and non-GAAP EPS of $1.35. CEO Christopher Boerner highlighted the approval of Zenbexus, a first-in-class CELMoD for multiple myeloma, and recent positive registrational data across several therapeutic areas.
Key points
- Third-quarter revenues rose 7% to $13.1 billion, with Growth Portfolio revenues up 12% to $7.7 billion.
- GAAP EPS was $1.05 and non-GAAP EPS was $1.35, both including a $(0.58) net impact from Acquired IPRD charges and licensing income.
- Full-year 2026 revenue guidance was raised to $49.75 billion–$50.25 billion; non-GAAP EPS guidance is $6.35–$6.55.
- Bristol Myers Squibb reported positive Phase 3 PANKU-Lung01 interim data for izalontamab brengitecan in EGFR-mutated NSCLC, positive Phase 2 ROSETTA Lung-107 data for pumitamig with BioNTech, and interim Phase 1 Breakfree-2 data for zola-cel in multiple sclerosis.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the third quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the information contained in or connected to the Company's website is not deemed to be incorporated by reference in this Current Report on Form 8-K. Item 7.01 Regulation FD Disclosure. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.